



OncoAlly™ Solid Tumor Analysis Test Requisition Form Page 1 of 2

Patient Name	Affix barcode label of Patient's
Date of Birth	sample here

Required □ Patient demographics Information □ ICD-10 codes □ Healthcare provider signature					☐ Signed informed consents ☐ Clinical information, pathology report and previous genetic reports ☐ Completed TRF and all clinical notes faxed to 508-302-8022						
OncoAlly™ Solid Tun	nor Analysis by	/ Variantyx									
(OA001)					Provides an oncology treatment optimization and therapy association analysis based on comprehensive molecular profiling of tumor and normal tissue. The test includes DNA sequence analysis (single nucleotide variants, deletions/insertions), duplication/deletions, copy number variants (CNVs), onco-pharmacogenomic variants, microsatellite instability status, HPV integration, tumor mutational burden, and RNA analysis, which detects gene fusions and complex rearrangements.						
Opt in for PD-L1, please select one: Opt-L1 22C3, FDA (KEYTRUDA®) Opt-L1 SP263, FDA (IMFINZI®) Opt-L1 28-8, FDA (OPDIVO®) Opt-L1 SP142, FDA (TECENTRIQ®) Provides combined positive score (CPS) / tumor proportion score (TPS)					5)						
(OA010) variants) and copy num inversions) of 87 genes Opt in for Genomic Unity® Pharmacogenomics Analysis Provides analysis of coresponse. The test includes the company of the company				equence analysis (single nucleotide variants, deletions/ insertions, characterized intronic nd copy number variants analysis (duplications/deletions, mobile element insertions and of 87 genes associated with hereditary cancer.							
	ic Unity® Phar	macogenon	nics Anal	lysis	Provides analysis of common variants associated with drug metabolism and pharmacogenetics response. The test includes sequence analysis and copy number variants analysis of known star alleles in 13 genes that were recommended by the FDA for predicted adverse drug reactions and drug response.						
Ordering Healthcare	Provider										
First Name			Last Na	ame				NPI#			
Facility Name						Phone					
Facility Address						Fax					
City			State		Zip Code Email						
Additional Report Re	cipients										
Name Phone					Fax Email						
Name Phone					Fax Email						
Detient Information											
Patient Information First Name			Last Na	ame			MI	DOB		Genetic Sex	
			<u> </u>							Male Female Other	
Address							ID / MR#			Gender identification (optional):	
City		State		Zip Code		Phone			Email		
Other Name (if different than listed above):				Pronouns	Treferred						
Please use this name in communications.							O E	inglish	OSpanish		
Patient Medical Histo	ory										
ICD-10			Primary ca	ancer diagnosis				Stag	le		
Radiation	Surgery Y /	/ N	PD-L	1 status) Negative	O >1%		10%	7.50%	Metastatic	
○ Yes ○ No │ Data				_	Negative \(\rightarrow \) >1% \(\rightarrow \)>50% \(\rightarrow \) Yes \(\rightarrow \) No ormed please provide a copy of the report with this test requisition form.						
Lines of therapy O O 1 O 2 O 3 O 4 O 5 Lines of therapy metastatic O 0 O 1 O 2 O 3 O 4 O 5											
*If 1-5 selected, please indicate the name of the therapies administered. *If 1-5 selected, please indicate the name of the therapies administered.											
Targeted therapy *(provide the drug name) Chen				 iemotherapy */ש	otherapy *(provide the drug name)				Immunotherapy *(provide the drug name)		



OncoAlly™
Solid Tumor Analysis
Test Requisition Form
Page 2 of 2

Patient Name	Affix barcode label of Patient's
Date of Birth	sample here

But the Bullion									
Patient Medical History									
For Gastric/ GEJ cancer - required: Hei	Her2 (ERBB2) status Optional: Other information, Previous history of transplant FISH: Opositive Negative IHC: 00 01 02 03								
	er2 (ERBB2) status SH: OPositive ON	tus O Negative O N/A IHC: O0 O1 O2 (02 C	Estrogen receptor Progesterone receptor 3			
	Cor: Estrogen receptor Progesterone receptor © ER+ © ER- © PR+ © PR-								
Tumor specimen information									
Specimen Type O Primary tumor O Metastatic	Tum	Tumor Tissue: Date of resection			ection/b	iopsy	Additional fixativ	ve use:	
Normal Specimen Information									
Sample Type Sample Will Be Coll O Blood O In-clinic		Collection date				Please check if your patient has had a: OBlood transfusion within the last two weeks OBone marrow transplant			
Specimen Retrieval									
Please send: 0 10-20 unstained	ed slides + one H&E s	lide () <i>If PD-L</i>	.1 is opted-	in, please se	nd additi	onal 5 unstained slide	?S		
Pathology Lab name:	Add	Address:				Phone:			
						Fax:			
Sample accession number:						Email:			
Pathologist Name:	MR	MRN:				Surgical number:			
Biopsy site:						Date of Specimen retrieval:			
Billing Information									
○ Insurance Billing									
Insurance Company		P			Pol	licy#		Group #	
Policy Holder First Name		Policy Holder Last Name				Policy Holder DOB			
Policy Holder Address Who is the Policy Holder? Patient Spouse Parent									
Employer's Address Patient status at time of sample collection: Office (non-hospital) Outpatient (requires discharge date below) or Not yet discharge date below)						below) or \(\cap \text{Not yet discharged}			
◯ Institutional Billing	0	Patient Payment							
An invoice will be sent to the institution above. Please contact us for alternate	Who should be contacted for billing purposes? An invoice of Payer Name: Payer Phor				pice will be sent to the patient email provided. Insurance will not be billed. Phone: Payer Email:				

Healthcare Provider's Statement

By my signature below, I indicate that I am the referring physician or authorized healthcare provider. My signature below certifies the medical necessity for the test and that the results of this test will inform the patient's ongoing treatment plan. I have explained the purpose of the test described above and obtained from the patient an informed consent, meeting the requirements of applicable law, for Variantyx or any laboratory Variantyx has contracted with, to (a) perform the test(s) described in this form; (b) obtain, receive, and release, test results and any corresponding medical information to the patient third party payer as necessary for reimbursement purposes; (c) retain test results, tissue, and information obtained from the patient, for an indefinite period of time; (d) use information obtained from the patient and the test results in accordance with applicable law, including de-identifying such information and disclosing the de-identified information for other purposes.

Healthcare provider signature ______ Date _____

